Anteris Technologies Global (NASDAQ:AVR) Sees Strong Trading Volume – Still a Buy?

Anteris Technologies Global Corp. (NASDAQ:AVR) saw strong trading volume on Monday. 1,462,601 shares traded hands during trading, an increase of 27% from the average daily volume of 1,147,313 shares. The stock last traded at $5.7950 and had previously closed at $6.31.

Wall Street Analyst Weigh In

Several analysts have issued reports on AVR shares. Barclays upgraded Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price target on shares of Anteris Technologies Global in a report on Wednesday, October 14th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Anteris Technologies Global has an average rating of “Hold” and a consensus target price of $14.00.

Anteris Technologies Global Stock Performance

The stock has a market cap of $545.78 million, a PE ratio of -2.87 and a beta of 2.02. The company’s 50-day moving average price is $7.43 and its 200 day moving average price is $7.38.

Anteris Technologies Global (NASDAQ:AVR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). The business had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same quarter in the prior year, the company posted ($0.58) earnings per share. As a group, equities research analysts predict that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder L1 Capital Pty Ltd purchased 648,455 shares of Anteris Technologies Global stock in a transaction dated Monday, October 5th. The shares were acquired at an average cost of $7.51 per share, with a total value of $4,869,897.05. Following the purchase, the insider owned 12,778,380 shares of the company’s stock, valued at approximately $95,965,633.80. The trade was a 5.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have bought 1,554,730 shares of company stock worth $11,694,513 and have sold 810,180 shares worth $7,270,974. 4.50% of the stock is currently owned by company insiders.

Institutional Trading of Anteris Technologies Global

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Anteris Technologies Global in the second quarter valued at approximately $56,846,000. Nantahala Capital Management LLC acquired a new stake in Anteris Technologies Global during the second quarter worth approximately $33,325,850. ADAR1 Capital Management LLC acquired a new stake in Anteris Technologies Global during the second quarter worth approximately $30,979,000. Perceptive Advisors LLC lifted its position in shares of Anteris Technologies Global by 104.4% during the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after buying an additional 1,750,000 shares during the last quarter. Finally, Militia Capital Management LLC purchased a new stake in shares of Anteris Technologies Global during the 1st quarter worth approximately $3,663,000.

About Anteris Technologies Global

Anteris Technologies Global is a medical device company focused on developing structural heart products for the treatment of heart valve disease. Its primary focus is transcatheter aortic valve replacement (TAVR), a minimally invasive procedure used to replace a diseased aortic valve without traditional open-heart surgery.

The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the function and hemodynamic performance of a healthy human aortic valve.